In an unbiased approach, we experimentally evolved A-419259-resistant populations of Flt3-ITD+ AML cell lines (which also express endogenous active Hck and Fgr) through gradual dose escalation, which required many months. The gene discussed is FLT3; the disease is acute myeloid leukemia.